Generation of a novel Slc7a9G105R mutant mouse identifies new biomarkers for cystinuria
Kidney International · 2026
DOI: 10.1016/j.kint.2026.06.050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International, 2026. Verfasst von Nirmal P Bhatt und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia; Bladder and Kidney Health Discovery Pr…. Hauptthemen laut MEDLINE: Cystinuria, Amino Acid Transport Systems, Basic, Amino Acid Transport System y+. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The University of Newcastle, University of Newcastle Hunter Medical Research Institute, National Collaborative Research Infrastructure Strategy.
Abstract (Originalsprache)
INTRODUCTION: Cystinuria is a rare inherited disease characterized by increased urinary cystine levels resulting in the formation of cystine stones in the urinary tract. Mutations in the genes encoding the cystine transporter complex, SLC3A1 and SLC7A9, are the primary drivers of the disease. Current mouse models used to study cystinuria rely on gene deficiency or spontaneous mutations in mice that do not accurately reflect the pathogenic mutations found in humans. METHODS: We generated a novel Slc7a9G105R knock-in mouse model in which glycine at position 105 is replaced by arginine, recapitulating the most common pathogenic mutation in human SLC7A9. Disease onset and progression were assessed using micro-CT imaging, fecal metagenomics, and urine and serum metabolomics and proteomics. RESULTS: Both male and female Slc7a9G105R mice developed a cystinuria phenotype by nine weeks of age, characterized by substantial cystine stone formation and increased urinary cystine, lysine, arginine, and ornithine. Slc7a9G105R mice displayed distinct serum and urinary metabolite profiles, mapped to dibasic amino acid pathways, and serum protein profiles, mapped to disease progression. Fecal metagenomics revealed that Slc7a9G105R mice had a heterogeneous microbiota with altered functional pathways, including increased L-cysteine biosynthesis. Antibiotic-induced depletion of the microbiota did not affect cystine stone burden but reduced urinary tract inflammation. Prophylactic or therapeutic dietary supplementation with alpha-lipoic acid reduced stone burden and inflammation, but it also caused urothelial damage. Untargeted metabolomics analysis following alpha-lipoic acid supplementation identified metabolites that can increase cystine solubility, reduce inflammation, and damage epithelial cells. Correlation analysis revealed novel serum metabolite biomarkers of stone burden, including 2-hydroxybutyric acid and 2-amino-2-thiazoline-4-carboxylic acid, which were also detected in human serum. CONCLUSIONS: Collectively, the Slc7a9G105R mutant mouse model offers a precise, rapid-onset, and translational platform for investigating cystinuria pathogenesis and evaluating potential therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia; Bladder and Kidney Health Discovery Program, School of Translational Medicine, Monash University, Melbourne,…
- Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
- Monash Genomics and Bioinformatics Platform, Monash Biomedicine Discovery Institute, Monash University, Melbourne, Victoria, Australia.
- Monash Proteomics and Metabolomics Platform, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria, Australia.
- Monash Proteomics and Metabolomics Platform, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.
- Department of Genome and Cancer, John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia.
Förderung
- The University of Newcastle
- University of Newcastle Hunter Medical Research Institute
- National Collaborative Research Infrastructure Strategy
- Monash University
- National Health and Medical Research Council
Zitieren
APA
Bhatt, N. P., Nguyen, T. T. H., Iacono, G., Rodriguez, G. R., Anderson, C. R. B., Perry, A., Barlow, C. K., Anderson, D., Burgio, G., Marsland, B. J., Jiang, S. H., Deshpande, A. V., & Starkey, M. R. (2026). Generation of a novel Slc7a9G105R mutant mouse identifies new biomarkers for cystinuria. Kidney International. https://doi.org/10.1016/j.kint.2026.06.050
Vancouver
Bhatt NP, Nguyen TTH, Iacono G, Rodriguez GR, Anderson CRB, Perry A, et al. Generation of a novel Slc7a9G105R mutant mouse identifies new biomarkers for cystinuria. Kidney International. 2026. doi:10.1016/j.kint.2026.06.050
BibTeX
@article{Bhatt2026,
author = {Bhatt, Nirmal P and Nguyen, Theresa T H and Iacono, Giulia and Rodriguez, Gabriel R and Anderson, Connor R B and Perry, Andrew and Barlow, Christopher K and Anderson, Dovile and Burgio, Gaetan and Marsland, Benjamin J and Jiang, Simon H and Deshpande, Aniruddh V and Starkey, Malcolm R},
title = {Generation of a novel Slc7a9G105R mutant mouse identifies new biomarkers for cystinuria},
journal = {Kidney International},
year = {2026},
doi = {10.1016/j.kint.2026.06.050}
}
EUVIMED